{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:28:56Z","timestamp":1761586136245,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.intimp.2020.107263","type":"journal-article","created":{"date-parts":[[2020,12,28]],"date-time":"2020-12-28T13:11:58Z","timestamp":1609161118000},"page":"107263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial"],"prefix":"10.1016","volume":"91","author":[{"given":"Chang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenliang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maofeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwei","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiguang","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.107263_b0005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrrheum.2014.64","article-title":"Mechanisms, impact and management of pain in rheumatoid arthritis","volume":"10","author":"Walsh","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2020.107263_b0010","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.intimp.2020.107263_b0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","article-title":"Rheumatoid arthritis","volume":"376","author":"Scott","year":"2010","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.intimp.2020.107263_b0020","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.107263_b0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.107263_b0030","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2020.107263_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0094-1","article-title":"The wide utility of rabbits as models of human diseases","volume":"50","author":"Esteves","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.intimp.2020.107263_b0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1080\/19420862.2017.1289302","article-title":"Humanization of rabbit monoclonal antibodies via grafting combined Kabat\/IMGT\/Paratome complementarity-determining regions: Rationale and examples","volume":"9","author":"Zhang","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2020.107263_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105807","article-title":"A randomized controlled dose-escalation study of SSS07, a humanized rabbit anti-human TNF alpha antibody, in healthy Chinese adults","volume":"75","author":"Wang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0050","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14740338.2016.1112375","article-title":"Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?","volume":"15","author":"Murdaca","year":"2016","journal-title":"Expert Opinion Drug Saf."},{"key":"10.1016\/j.intimp.2020.107263_b0055","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bcp.13039","article-title":"Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira((R)) in healthy subjects","volume":"82","author":"Hyland","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0060","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/bcp.13245","article-title":"Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab\/Humira, in healthy subjects","volume":"83","author":"Puri","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0065","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.380","article-title":"Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects","volume":"6","author":"Hillson","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.intimp.2020.107263_b0070","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/jcph.1278","article-title":"Safety, pharmacokinetics, and pharmacodynamics of multiple rising doses of BI 655064, an antagonistic anti-CD40 antibody, in healthy subjects: a potential novel treatment for autoimmune diseases","volume":"58","author":"Schwabe","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s40360-019-0376-9","article-title":"A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects","volume":"20","author":"Bush","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.intimp.2020.107263_b0080","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.2147\/DDDT.S169082","article-title":"Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects","volume":"12","author":"Shin","year":"2018","journal-title":"Drug Des. Develop. Therapy"},{"issue":"15354\u201315359","key":"10.1016\/j.intimp.2020.107263_b0085","doi-asserted-by":"crossref","first-page":"15354","DOI":"10.1073\/pnas.1510944112","article-title":"Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies","volume":"112","author":"Townsend","year":"2015","journal-title":"PNAS"},{"key":"10.1016\/j.intimp.2020.107263_b0090","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jim.2013.07.010","article-title":"Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference","volume":"396","author":"Weeraratne","year":"2013","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.intimp.2020.107263_b0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","article-title":"Dealing with immunogenicity of biologicals: assessment and clinical relevance","volume":"21","author":"Wolbink","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"issue":"765\u2013773","key":"10.1016\/j.intimp.2020.107263_b0100","article-title":"A novel human anti-interleukin-1\u03b2 neutralizing monoclonal antibody showing in vivo efficacy","volume":"6","author":"Goh","year":"2014","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2020.107263_b0105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/ecco-jcc\/jjv004","article-title":"Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease","volume":"9","author":"Steenholdt","year":"2015","journal-title":"J. Crohn's Colitis"},{"key":"10.1016\/j.intimp.2020.107263_b0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","article-title":"A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res. Therapy"},{"key":"10.1016\/j.intimp.2020.107263_b0115","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1111\/all.13471","article-title":"IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution","volume":"73","author":"Vultaggio","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.intimp.2020.107263_b0120","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ab.2009.04.021","article-title":"Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards","volume":"390","author":"Stubenrauch","year":"2009","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.intimp.2020.107263_b0125","unstructured":"Immunogenicity Testing of Therapeutic Protein Products -Developing and Validating Assays for Anti-Drug Antibody Detection (https:\/\/www.fda.gov\/media\/119788\/download)."},{"key":"10.1016\/j.intimp.2020.107263_b0130","article-title":"Current status and challenge of biopharmaceutical immunogenicity","author":"Lu","year":"2007","journal-title":"Chinese J. New Drugs"},{"key":"10.1016\/j.intimp.2020.107263_b0135","first-page":"483","article-title":"WANG Q: Technical Considerations on the Study and Evaluation of the Biosimilars' Immunogenicity","volume":"50","author":"Wang","year":"2015","journal-title":"Chin. Pharmaceut. J."},{"key":"10.1016\/j.intimp.2020.107263_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaip.2018.04.007","article-title":"The kinetics of antidrug antibodies, drug levels, and clinical outcomes in infliximab-exposed patients with immune-mediated disorders","volume":"6","author":"Nencini","year":"2018","journal-title":"J. Allergy Clin. Immunol. Practice"},{"key":"10.1016\/j.intimp.2020.107263_b0145","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/1744666X.2020.1684264","article-title":"Hypersensitivity reactions to biologics used in rheumatology","volume":"15","author":"Matucci","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.intimp.2020.107263_b0150","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1089\/jir.2012.0139","article-title":"Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions","volume":"34","author":"Vultaggio","year":"2014","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"10.1016\/j.intimp.2020.107263_b0155","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1136\/annrheumdis-2016-211035","article-title":"Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies","volume":"76","author":"van Schie","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.107263_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.102373","article-title":"The immunobiology of mTOR in autoimmunity","volume":"110","author":"Suto","year":"2020","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2020.107263_b0165","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.coph.2011.05.003","article-title":"Neuroprotective, immunosuppressant and antineoplastic properties of mTOR inhibitors: current and emerging therapeutic options","volume":"11","author":"Pignataro","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0170","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/BOR.0000000000000687","article-title":"Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases","volume":"32","author":"Wyman","year":"2020","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.107263_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100779","article-title":"Risk of dyslipidemia associated with VEGF\/VEGFR inhibitors: a meta-analysis","volume":"13","author":"Dai","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.intimp.2020.107263_b0180","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jcph.428","article-title":"Safety considerations of mammalian target of rapamycin inhibitors in tuberous sclerosis complex and renal transplantation","volume":"55","author":"Somers","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.intimp.2020.107263_b0185","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/14712598.2019.1571580","article-title":"GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods","volume":"19","author":"von Richter","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.intimp.2020.107263_b0190","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","article-title":"A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab","volume":"76","author":"Kaur","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"680\u2013695","key":"10.1016\/j.intimp.2020.107263_b0195","article-title":"Transmembrane TNF-dependent uptake of anti-TNF antibodies","volume":"9","author":"Deora","year":"2017","journal-title":"mAbs"},{"key":"10.1016\/j.intimp.2020.107263_b0200","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41562-017-0189-z","article-title":"Redefine statistical significance","volume":"2","author":"Benjamin","year":"2018","journal-title":"Nat. Hum. Behav."},{"key":"10.1016\/j.intimp.2020.107263_b0205","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2018.1536","article-title":"The proposal to lower P value thresholds to.005","volume":"319","author":"Ioannidis","year":"2018","journal-title":"JAMA"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920337309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:23:35Z","timestamp":1761585815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920337309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":41,"alternative-id":["S1567576920337309"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107263","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.107263","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107263"}}